The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis.

ABSTRACT:

Background

Immune checkpoint inhibitor (ICI) therapy is an emerging option for advanced endometrial cancer (EC). Mismatch repair (MMR) status is widely regarded as a biomarker predictive of response to ICIs. The predictive value of MMR based on small, single-arm trials, however, is conflicting. In this meta-analysis, we aimed to assess the activity of single-agent ICI in advanced EC, and compared the magnitude of treatment benefit in MMR deficient (dMMR) and MMR proficient (pMMR) EC.

Methods

We carried out an electronic search to identify prospective trials of single-agent ICI in advanced EC. Data on objective response rate (ORR) and progression-free survival (PFS) were extracted and pooled. ORR was estimated using the inverse variance method and subgroup difference by MMR s

SUBMITTER: Kok PS 

PROVIDER: S-EPMC9808459 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature